Multiple compression — 35× trailing leaves no cushion if the acquisition engine or industrial demand slows
One-line thesis. AMETEK is a genuinely elite serial-acquirer industrial compounder — 37% gross margin, 26% operating margin, a fortress balance sheet and a decades-long record of buying niche instrument businesses and never taking a goodwill write-off — but at 35× trailing earnings on only mid-single-digit organic growth, the price already pays for the quality, so we rate it Watch and wait for a better entry.
◆ Synthos call — HoldAME is a solid business largely reflected at ~$232 — fine to keep, no reason to chase; it gets interesting again below ~$197.
Downside Risk (lower = safer)
5/10 · Moderate
Fortress balance sheet (net-debt/EBITDA 0.7×) & beta 0.99 — but 35× trailing on only mid-single-digit organic growth.
Growth Quality
7/10 · High
~6% forward EPS CAGR, 37% gross / 26% op margin, ROIC ~11%, durable serial-acquirer moat — quality but not fast.
Exponential Potential
3/10 · Low
Mid-single-digit growth, decelerating after 2026-27; a mature $54B compounder — no multibagger runway.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 20%/yrTo justify today’s $235, earnings would have to compound roughly 20% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
AMETEK builds specialized measuring instruments and electric motors — the sensors, gauges, connectors and precision devices that go inside aircraft, factories, labs, medical scanners and power plants. You've never seen its name on a shelf, but its parts are buried inside thousands of machines. Its real skill is buying small, high-quality niche manufacturers and running them better — it has done this hundreds of times over decades without a single bad write-down, which is rare.
The catch: the stock is expensive. You're paying about $35 for every $1 the company earns, which only makes sense if it keeps growing — and it's a big, mature company now, so it grows steadily but slowly (mid-single digits). Our verdict is Watch: a great business, but the price already assumes everything goes right. Wait for a dip.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). Financially rock-solid with very little debt and a stock that doesn't swing wildly — but because it's priced high, a stumble would sting.
Growth Quality 7/10 (good). A very profitable, well-run business — just not a fast grower.
Exponential Potential 3/10 (low). It's already big and growing slowly; don't expect it to double any time soon.
The one big worry: the price. If the acquisition machine slows or factory demand softens, a high-priced stock can fall hard even if the business is fine.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = AME · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$234.62
Market cap$54B
P/E trailing10×
P/E FY26E / FY27E29× / 27×
EV / Sales7.3×
EV / EBITDA23.5×
Gross margin36.6%
Net margin20.1%
Dividend yield0.55%
Beta0.99
52-wk range$176 – $242
RSI(14)59
50 / 200-DMA$231 / $214
12-mo return+28% (SPY +21%)
Street target$253 ($215–$303)
Analyst grades20 Buy · 9 Hold · 0 Sell
FMP ratingA-
Next earnings2026-08-05
What the experts actually said 6 traceable claims on AME · showing the highest-conviction voices
“Management are excellent capital allocators—hundreds of acquisitions, never a goodwill write-off; buy/build differentiated cash-generative businesses.”
Business Breakdownsbullishconviction 852024-10-14business_breakdowns--daYqwbXSE0:5578bdd111
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
AMETEK (NYSE: AME) is a ~$54B global manufacturer of electronic instruments and electromechanical devices, founded 1930, headquartered in Berwyn, PA, run by CEO David Zapico. It operates as a decentralized collection of niche businesses under two segments, and its core competency is the "AMETEK Growth Model" — buying differentiated, cash-generative niche manufacturers and improving their margins. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
By segment: Electronic Instruments Group (EIG) $4.92B (66%) — process/analytical instruments, aerospace sensors, power/test & measurement, medical diagnostics; Electromechanical Group (EMG) $2.48B (34%) — engineered connectors, precision motion control, thermal management, specialty materials, aerospace MRO.
By geography: roughly ~53% United States, the balance international — Asia ~$1.49B, EU ~$1.09B, other non-US ~$0.73B, plus UK. (FMP's FY25 geo file drops the explicit US line; FY24 showed US $3.65B of $6.94B ≈ 53%, and the mix is stable.) International exposure is a tariff/FX and supply-chain risk (§11).
Q1'26 (latest print) showed the model working: sales +11%, record orders +23%, record backlog, adjusted operating margin 26.8% (+50bps), EMG operating income +33%.
2. The expert thesis — why the panel is (thinly) bullish (traceable)
Honesty first: AMETEK has almost no expert coverage in the Synthos KB. Total claims = 6, net-bullish voices = 1. This verdict is fundamentals- and quant-driven, not conviction-driven. There is no broad expert panel here — treat the "thesis" below as a single high-quality data point, not a chorus.
The serial-acquirer / capital-allocation thread — Business Breakdowns (business_breakdowns--daYqwbXSE0:5578bdd111, bullish, conviction 85, skill 1.0): "Management are excellent capital allocators — hundreds of acquisitions, never a goodwill write-off; buy/build differentiated cash-generative businesses." This is the whole bull case in one line, and it is corroborated by the numbers: FY23 goodwill impairment $0, a clean record, and ROIC ~11% on an acquisition-heavy balance sheet (70% of assets are goodwill/intangibles — see §5).
That is the only reconciled net-bullish claim. No high-skill macro or sector voice (of the kind that anchors the LLY note) covers AME. So the burden of proof falls entirely on the financials and the valuation math below — which is exactly why the verdict is a disciplined Watch, not a conviction Buy.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Net-debt/EBITDA 0.7×, beta 0.99, interest coverage 24×, tiny 3% max drawdown — financially very sturdy. Offsetting: 35× trailing / 23.5× EV/EBITDA on mid-single-digit growth leaves no valuation cushion, and it's cyclically tied to industrial/aero capex.
Growth Quality
7 · High
37% gross / 26% operating / 20% net margin, ROIC ~11%, ROE 14%, FCF conversion ~93% of net income, a durable serial-acquirer moat — but only ~6% forward EPS CAGR, which caps the score below the megacap compounders.
Exponential Potential
3 · Low
Revenue CAGR FY25→FY30E ~5%, EPS ~6%, and the second derivative turns negative after 2026-27. A mature $54B name in a fragmented but slow-growing end-market — steady, not exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Orders momentum (+23% Q1) sustains; M&A pipeline deploys the ~$1.7B FCF into accretive deals; organic re-accelerates. FY27E EPS beats to ~$9.20 (vs $8.80 cons); multiple holds premium ~30×.
~$276 (+18%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$8.80; a high-quality mid-single-digit compounder earns a ~26× multiple.
~$232 (−1%)
Bear
Industrial/aero capex softens, M&A slows or a deal disappoints, tariffs bite; FY27E EPS misses to ~$8.30; multiple de-rates to ~22× as the growth premium unwinds.
~$183 (−22%)
Synthos fair value = the base case, ~$232 (−1%), with the full $183–$276 span as the honest range. Our anchor sits below the Street's $252.55 consensus: we think the market is already paying for the acquisition optionality, so the risk/reward is roughly symmetric-to-negative at today's price. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AME is a high-quality compounder with low exponential potential:
Acceleration (the 2nd derivative) is flat-to-negative: revenue growth is estimated at +8% (FY26E) → +6% (FY27E) → +6% (FY28E) → +3% (FY29E) → +4% (FY30E). Orders spiked +23% in Q1'26, which is the genuine bull tell, but the analyst path assumes that normalizes. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — AME is squarely a compounder, not an accelerant.
Room to run: AMETEK's end-markets (niche instruments, sensors, motion control) are fragmented and large in aggregate, which feeds the M&A runway — but organic category growth is GDP-plus, not exponential. At $54B the law of large numbers plus single-digit organic growth means no realistic multibagger path from here.
Reinvestment runway (the one real lever): ~$1.7B annual FCF redeployed into accretive acquisitions is the engine that has historically turned ~5% organic into low-double-digit EPS growth over a cycle. If that engine keeps compounding, the bull case is where the upside lives — but it depends on deal availability and discipline, not a secular demand wave.
Exponential Potential: Low. Own it (if at all) for durable mid-single-digit-to-low-double-digit EPS compounding via disciplined M&A, not for a fast multibagger. This is a Core-quality industrial, never a Degen-tier name.
Revenue: FY25 $7.40B, +6.6% (FY24 $6.94B, +5.2% on FY23 $6.60B). Steady mid-single-digit growth, augmented by bolt-on M&A.
Quarterly trajectory: Q1'25 $1.73B → Q2 $1.78B → Q3 $1.89B → Q4 $2.00B → Q1'26 $1.93B (+11.3% YoY). Q1'26 orders +23%, record backlog — the leading indicator is strong.
Margins (best-in-class for the group): gross 36.6% TTM, operating 26.2%, EBITDA 31.1%, net 20.1%. Q1'26 adjusted operating margin 26.8%, up 50bps YoY with 160bps of core margin expansion.
Earnings: net income $1.48B FY25 (+7.6%); GAAP diluted EPS $6.40; TTM P/E 35.3×. Adjusted EPS runs higher (FY25 adj-basis ~$7.37; Q1'26 adj EPS $1.97 vs GAAP $1.74 — the gap is acquisition-related intangible amortization).
Cash flow: operating CF $1.80B, capex only −$130M (capex/revenue ~1.7% — asset-light), FCF $1.67B FY25, ~93% of operating CF and >100% of net income. Elite cash conversion.
Balance sheet (fortress): total debt $2.34B, cash $0.46B, net debt $1.89B, net-debt/EBITDA ~0.7×, interest coverage ~24×. Note: goodwill + intangibles are $11.3B of $16.1B total assets (~70%) — the flip side of a serial acquirer; tangible book is negative. This is normal for the model but means book value is not a floor.
6. Valuation — priced in or room?
There is no way to call AME cheap: 35× trailing EPS, 7.3× EV/sales, 23.5× EV/EBITDA, ~5× book. FMP's letter rating is A- (strong on ROA/ROE, weak on P/E and P/B — i.e. great business, rich price). The bull's defense is the forward curve: on consensus EPS the P/E is 29× (FY26E) → 27× (FY27E) → ~24× (FY30E) — the multiple compresses slowly because growth is only mid-single-digit, so a flat price still leaves you paying a mid-20s multiple in 2030. That's the crux: unlike a fast grower, AME's multiple does not melt away with time.
A reverse read: at $234.62 the market is capitalizing ~$8.14 of FY26E adjusted EPS at ~29×, which prices in continued flawless execution and accretive M&A. Street targets (context): consensus $252.55, high $303, low $215. Our $232 base fair value is below consensus — we give less credit than the Street to the M&A optionality being underwritten at today's price. Not a value buy; a quality-industrial-at-a-full-price that we'd rather own 10–15% cheaper.
7. Technicals (from the tech block)
Trend:up. $234.62 sits above the 50-DMA ($230.93) and 200-DMA ($214.10), with the 50 above the 200 (golden-cross posture). MACD +2.65 (positive).
Location:−3.0% off the 52-week high ($241.94), +33% off the 52-week low ($176.44) — near highs, and the max drawdown from peak is only −3%. A calm, low-volatility uptrend.
Momentum: RSI(14) 59 — firm but not overbought (<70), so no stretched-entry warning.
Relative strength: AME +28.2% 12-mo vs SPY +20.6% (modest outperformance), but lagging QQQ +30.3%; +7.3% 3-mo vs SPY +13.7% and QQQ +22.0% — it has underperformed both over the last quarter. A steady industrial, not a momentum leader.
Read: technicals are constructive but unremarkable — an orderly uptrend near highs. Nothing here forces a buy; a pullback toward the rising 200-DMA (~$214) would improve the risk/reward materially given our $232 base fair value.
8. Moat & competitive position
AMETEK's moat is operational and structural rather than a single product: (1) a decentralized serial-acquirer playbook — hundreds of niche acquisitions, disciplined pricing, and a clean record of never taking a goodwill write-off (business_breakdowns--daYqwbXSE0:5578bdd111); (2) niche market leadership — its instruments and devices are designed into long-cycle aerospace, process, and medical platforms with high switching costs; (3) margin engineering — the "AMETEK Growth Model" reliably lifts acquired-business margins, driving the 26%+ operating margin. The durable ~11% ROIC on a goodwill-heavy base is the proof the model compounds value, not just assets.
Peer set (market cap): the closest quality-compounder comp is Roper Technologies ($36.8B) — same serial-acquirer DNA. Broader industrial peers: Rockwell Automation ($52.5B), Otis ($28.1B), Carrier ($58.2B), Xylem ($28.1B), Ferguson ($44.7B), Fastenal ($55.8B), W.W. Grainger ($63.4B), Ferrovial ($48.8B). Symbotic ($4.9B) is a small, faster-growing outlier, not a true comp. AME trades at a premium multiple justified only by its margin and capital-allocation record.
9. Management, capital allocation & guidance
Capital allocation: the whole thesis. ~$1.7B FCF/yr deployed primarily into accretive bolt-on M&A (FY25 acquisitions −$933M), plus a modest dividend (~0.6% yield, payout ~19%) and opportunistic buybacks (−$434M FY25). The explicit corporate objective is "double-digit percentage growth in EPS over the business cycle and a superior return on total capital."
Insider activity: the sampled window (2026-03 to 2026-05) shows routine option-exercise, award, and small director activity — no cluster of alarming discretionary selling. Normal.
Management's own guidance (half-weighted — their book): The SEC 8-K (Q1'26 earnings release, dated 2026-04-30) is a real earnings release and management raised full-year guidance. In management's own words: "For 2026, we now expect overall sales to be up high single digits… Adjusted earnings per diluted share are now expected to be in the range of $7.94 to $8.14, up 7% to 10% … an increase from our prior guidance range of $7.87 to $8.07." For Q2'26: sales up high single digits, adjusted EPS $1.96–$2.00 (up 10–12%). CEO Zapico cited "record backlog, momentum across attractive markets, and the proven strength… of the AMETEK Growth Model," and flagged "meaningful capital to deploy on strategic acquisitions." We half-weight this (management talks its own book), but the guidance raise plus record orders is a genuine positive signal.
10. Catalysts & what to watch
Next earnings: 2026-07-30 (Q2'26; Street EPS $1.99, revenue ~$1.95B; management adj-EPS guide $1.96–$2.00). Watch organic growth vs orders — can the +23% Q1 order surge convert to sustained organic sales?
M&A cadence: deal announcements and the multiples paid — the engine of the whole compounding story.
Backlog & book-to-bill: the record backlog is the leading indicator; a rollover would be the first warning.
End-market demand: aerospace, process/industrial, and semiconductor capex cycles.
Margins: continued core margin expansion (160bps in Q1'26) vs tariff/input-cost pressure.
Thesis tripwires (what would change the call): two consecutive quarters of organic deceleration or a book-to-bill below 1; a large, expensive, out-of-pattern acquisition; core-margin compression; or a de-rating that finally brings the multiple back toward the mid-20s (which would flip us more constructive on price).
11. Key risks
Valuation / de-rating (the primary risk): 35× trailing on mid-single-digit organic growth leaves no cushion; any growth or M&A disappointment can compress the multiple hard.
M&A dependency: the compounding math relies on continuously finding and integrating accretive deals at sensible prices — deal scarcity or a costly misstep breaks the model.
Cyclicality: industrial, aerospace, and semiconductor capex exposure ties results to the economic cycle.
Tariffs / trade / FX: ~47% international revenue and a global supply chain; management explicitly flags tariffs, trade disputes, and supply-chain disruption as risk factors.
Goodwill-heavy balance sheet: ~70% of assets are goodwill/intangibles and tangible book is negative — the clean write-off record is reassuring, but a bad-deal cycle would test it.
Thin expert coverage: only 1 net-bullish KB voice (6 claims) — this is a quant/fundamentals call with no deep external conviction to lean on.
12. Verdict, position sizing & monitoring
Watch. AMETEK is a genuinely elite industrial compounder — 37% gross margin, 26% operating margin, ~93% FCF conversion, a 0.7× net-debt/EBITDA fortress balance sheet, and a decades-long serial-acquirer record with never a goodwill write-off (business_breakdowns--daYqwbXSE0:5578bdd111). Management just raised FY26 guidance on record orders (+23%) and record backlog. But at 35× trailing / 29× forward on ~6% EPS growth, our base-case fair value of ~$232 sits essentially at today's price and below the Street's $252.55 — the quality is real, and so is the full price. The right discipline is to wait for a better entry rather than pay up for perfection.
Sizing: not a buy here. If already owned, treat as a ~2–3% quality-industrial holding and let it compound; new money should wait for a pullback toward the rising 200-DMA (~$214) or a de-rate toward a mid-20s multiple.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $234.62.
Single biggest risk: multiple compression — a high-priced stock can fall hard even when the business is fine, if M&A or industrial demand slows.
Provenance & disclosures
Traceability: 6 KB claims, breadth 1 net-bullish voice, top skill 1.0 (Business Breakdowns), last claim 2024-10-14 — the one cited claim (business_breakdowns--daYqwbXSE0:5578bdd111) reconciles to a real claim_id. Fabricated conviction is structurally impossible (claim-ID reconciliation). This is a fundamentals/quant-driven verdict, not a conviction-track call.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim 2024-10-14. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: the FY26 guidance in §9 is management's own book (SEC 8-K, 2026-04-30), half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").